Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
May 23, 2023
Assignees:
UNIVERSITY OF WASHINGTON, THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Daniel Adriano Silva Manzano, Shawn Yu, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey, Umut Ulge
Abstract: Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
April 25, 2023
Assignee:
COCOON BIOTECH INC.
Inventors:
Scott Delisle, Lindsey Easthon, Michael Santos, Ailis Tweed-Kent
Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.
Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
April 18, 2023
Assignee:
Rutgers, The State University of New Jersey
Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
March 14, 2023
Assignee:
NEUBASE THERAPEUTICS, INC.
Inventors:
Danith H. Ly, Shivaji A. Thadke, Ramesh U. Batwal, Dietrich A. Stephan
Abstract: Disclosed herein is a use of an adenosine triphosphate (ATP) binding cassette (ABC) transporter peptide inhibitor HX-12C. This disclosure also discloses a method of treating a tumor with multidrug resistance mediated by the ABC transporter using a combination of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug. Moreover, this disclosure also provides a composition for treating a tumor with multidrug resistance mediated by an ABC transporter, consisting of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug.
Type:
Grant
Filed:
May 18, 2021
Date of Patent:
February 28, 2023
Assignee:
HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
Abstract: The present invention relates to a liquid pharmaceutical composition comprising a peptide of SEQ ID NO.: 2 as an active pharmaceutical ingredient. The composition of the present invention is suitable for medical use in humans, for example in the treatment of disorders of a metabolic syndrome or diabetes or obesity or for reduction of excess food intake.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
February 28, 2023
Assignee:
SANOFI
Inventors:
Marta Venczel, Nino Meyer, Walter Kamm, Norbert Nagel, Bruno Baumgartner
Abstract: The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.
Type:
Grant
Filed:
September 24, 2018
Date of Patent:
February 21, 2023
Assignee:
Heidelberg Pharma Research GmbH
Inventors:
Francesca Gallo, Barbara Korsak, Christoph Mueller, Torsten Hechler, Andreas Pahl, Michael Kulke, Werner Simon, Christian Lutz
Abstract: Methods and systems for control of solid phase peptide synthesis are generally described. Control of solid phase peptide synthesis involves the use of feedback from one or more reactions and/or processes (e.g., reagent removal) taking place in the solid phase peptide synthesis system. In some embodiments, a detector may detect one or more fluids flowing across a detection zone of a solid phase peptide synthesis system and one or more signals may be generated corresponding to the fluid(s). For instance, an electromagnetic radiation detector positioned downstream of a reactor may detect a fluid exiting the reactor after a deprotection reactor and produce a signal(s). In some embodiments, based at least in part on information derived from the signal(s), a parameter of the system may be modulated prior to and/or during one or more subsequent reactions and/or processes taking place in the solid phase peptide synthesis system.
Type:
Grant
Filed:
May 15, 2020
Date of Patent:
February 21, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Dale Arlington Thomas, III, Alexander James Mijalis, Bradley L. Pentelute, Mark David Simon, Surin Mong
Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Abstract: Carbamathione agent protects brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimizes the size of infarcts that develop as a result of the injury.
Abstract: The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 ? (Angstroms) or less.
Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.
Type:
Grant
Filed:
April 15, 2020
Date of Patent:
February 7, 2023
Assignee:
AXCELLA HEALTH INC.
Inventors:
William Comb, Sean Carroll, Raffi Afeyan, Michael Hamill
Abstract: The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
January 31, 2023
Assignee:
Centro de Ingeniería Genética y Biotecnología
Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.
Type:
Grant
Filed:
March 30, 2020
Date of Patent:
January 31, 2023
Assignee:
University of Mississippi Medical Center
Inventors:
Gene L. Bidwell, III, Alejandro R. Chade
Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Type:
Grant
Filed:
July 20, 2021
Date of Patent:
January 24, 2023
Assignee:
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Abstract: The present invention relates to a targeting module comprising a chemically synthesized peptide binding moiety specific for a human cell surface protein or protein complex, a kit comprising the targeting module and a vector or a cell comprising a nucleic acid encoding a universal chimeric antigen receptor and the use for the treatment of cancer, infections and autoimmune disorders.
Abstract: Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
January 10, 2023
Assignee:
NovMetaPharma Co., Ltd.
Inventors:
Hoe-Yune Jung, Heonjong Lee, Dohyun Lee